+40.9%
TTWO vs GSK
+47.2%
-6.3%
-51.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | 0.0% | -0.7% | -0.7% |
| 7D | +0.4% | -3.5% | +3.9% | +0.5% |
| 30D | -11.3% | -3.4% | -7.9% | -11.2% |
| 3M | +1.6% | -8.1% | +9.7% | +1.9% |
| 6M | +2.1% | -11.1% | +13.2% | +2.4% |
| YTD | -15.8% | +0.7% | -16.6% | -16.4% |
| 1Y | -12.6% | +20.1% | -32.7% | -14.5% |
| 3Y | +48.2% | +46.1% | +2.1% | +40.9% |
| All | +40.9% | +47.2% | -6.3% | +32.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling